• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » SentreHeart closes $35m Series D for Lariat trial

SentreHeart closes $35m Series D for Lariat trial

September 27, 2016 By Sarah Faulkner

SentreHeartSentreHeart said today that it landed a $35 million Series D round from Deerfield Management, with funds slated to support a trial evaluating its Lariat suture delivery system.

The Amaze trial aims to investigate the use of Lariat for catheter-based left atrial appendage closure in patients with persistent atrial fibrillation, the Redwood City, Calif-based company said.

SentreHeart touted recent studies that show Lariat can mechanically close left atrial appendages and can isolate electrical activity, a known contributor for atrial fibrillation.

The company won 510(k) clearances from the FDA in 2006, 2009, and 2014. Last year, Variant won CE Mark approval in the European Union.

“We are excited to have Deerfield as an investment partner in SentreHeart,” CEO & president Russ Seiber said in prepared remarks. “Our objective is to address improved treatment strategies for AFib of which the LAA plays a critical role in the restoration and maintenance of normal sinus rhythm, as well as, protection against thromboembolism. The Amaze trial is key to fulfilling our commitment to developing clinical evidence with potential to significantly improve the lives of patients with atrial fibrillation.”

“We are very pleased to support SentreHeart and the landmark Amaze trial. The Lariat technology addresses the clinical needs and requirements for LAA closure in AFib patients with advantages unmatched by other closure options,” Deerfield partner Ted Huber added. He was appointed to SentreHeart’s board of directors, according to the company. “The technology developed by SentreHeart is creating a new path to improved outcomes in the treatment of AFib, as well as redefining the clinical role of LAA closure.”

Filed Under: Cardiovascular, Clinical Trials, Funding Roundup Tagged With: SentreHeart

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy